Drugs / WRSs2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01336699 | Jan 2013 → May 2015 | shigellosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04242264 | Oct 2022 → Mar 2024 | shigellosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WRSs2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04242264 ↗ |
| Modality | Vaccine | “WRSs2 is a live, attenuated Shigella sonnei vaccine product” NCT01336699 ↗ |
| Route | Oral | “given orally” NCT01336699 ↗ |